Alcoholic Beverage Research Institute, Daesun Distilling Co. Ltd. , Busan , South Korea.
J Enzyme Inhib Med Chem. 2011 Sep 30. doi: 10.3109/14756366.2011.615746.
This study aimed to evaluate the effects of Monascus purpureus-fermented Angelicae gigantis Radix (FAG) on body weight gain, visceral fat accumulation, biochemical markers of obesity, and the mRNA expression levels of various genes involved in adipogenesis in a high-fat-diet (HFD)-induced rat model of obesity. Effect of nodakenin isolated from Angelicae gigantis on 3T3-L1 preadipocyte differentiation was also investigated in vitro. Male Sprague-Dawley rats were randomly divided into five groups (n = 6 per group) based on five dietary categories: HFD control, HFD + 2.5% (w/w) AG, HFD + 5% AG, HFD + 2.5% FAG, and HFD + 5% FAG. Present study investigated nodakenin isolated from AG and FAG roots by measuring fat accumulation in 3T3-L1 preadipocyte using Oil Red O staining. FAG administration effectively lowered the body weight gain, visceral fat accumulation, and hepatic and serum lipid and leptin concentrations in obese rats. In addition, FAG administration significantly reduced the mRNA expression levels of adipose tissue genes encoding adipocyte protein 2 (aP2), peroxisome proliferator-activated receptor γ 2 (PPARγ2), and CCAT/enhancer-binding protein α (C/EBPα) as compared with HFD group. Furthermore, nodakenin reduced the fat accumulation in differentiated 3T3-L1 adipocytes in a dose-dependent manner. FAG ameliorates HFD-induced obesity, probably by modulating multiple genes associated with adipogenesis in the visceral fat tissue of rats. Accordingly, fermented Angelicae gigantis may be an ideal candidate for obesity relief.
本研究旨在评估红曲米发酵当归(FAG)对高脂肪饮食(HFD)诱导肥胖大鼠体重增加、内脏脂肪积累、肥胖生化标志物和脂肪生成相关基因 mRNA 表达水平的影响。此外,还研究了从当归中分离得到的当药宁对 3T3-L1 前体脂肪细胞分化的影响。雄性 Sprague-Dawley 大鼠随机分为五组(每组 6 只),根据五种饮食类别进行分组:HFD 对照组、HFD+2.5%(w/w)AG、HFD+5%AG、HFD+2.5%FAG 和 HFD+5%FAG。本研究通过油红 O 染色测量 3T3-L1 前体脂肪细胞中的脂肪积累来研究从 AG 和 FAG 根部分离得到的当药宁。FAG 给药可有效降低肥胖大鼠的体重增加、内脏脂肪积累以及肝和血清脂质和瘦素浓度。此外,与 HFD 组相比,FAG 给药可显著降低脂肪组织基因编码脂肪细胞蛋白 2(aP2)、过氧化物酶体增殖物激活受体 γ 2(PPARγ2)和 CCAT/增强子结合蛋白 α(C/EBPα)的 mRNA 表达水平。此外,当药宁呈剂量依赖性地减少分化的 3T3-L1 脂肪细胞中的脂肪积累。FAG 可改善 HFD 诱导的肥胖,可能是通过调节大鼠内脏脂肪组织中与脂肪生成相关的多个基因。因此,发酵当归可能是一种理想的肥胖缓解候选物。